Sign in:
 Email
 Password  save:
  
 Company Reports 
 
 
Membership is free, please Sign Up.
  
My Recent Searches
  Help
  
   
 
 
Get Insiders for : 
Cryolife Inc (CRY)  
$25.65 0.80 (3.22%) as of 4:30 Fri 6/28


Download
   
Exchange: New York Stock Exchange
Security Type: Common
Shares Out: 37,860,000
Market Cap: 971.11(M)
Last Volume: 1,330,410 Avg Vol: 218,328
52 Week Range: $12.33 - $24.85
Level I Sector: Health Care
Level II Sector: Health Services
Level III Sector: Specialized Health Services

Member Indexes:
    S&P COMPOSITE 1500     NYSE COMPOSITE
    S&P SMALLCAP 600

Rankings:
     
Insider 3 Months    :   -
Insider 6 Months    :   -
Insider 3/6 Months :   -
Guru Rank Number :  -
Guru Rank Value     :  -
Guru Occurances    :  -

 

            6 Months   1 Year   2 Year  
 
Company Profile   Artivion is engaged in the manufacturing, processing, and distribution of medical devices and implantable human tissues used in cardiac and vascular surgical procedures for patients with aortic disease. Co. has the following product families: aortic stents and stent grafts, surgical sealants, On-X® mechanical heart valves and related surgical products, and implantable cardiac and vascular human tissues. Aortic stents and stent grafts include JOTEC® stent grafts and surgical products, the Ascyrus Medical Dissection Stent hybrid prosthesis, and the NEXUS® endovascular stent graft system. Surgical sealants include BioGlue® Surgical Adhesive products.

 
 
Summary  (Direct Transactions Only) 3 Months 6 Months 12 Months 24 Months
Total Shares Bought 0 0 0 0
Total Buy Value $0 $0 $0 $0
Total People Bought 0 0 0 0
Total Buy Transactions 0 0 0 0
Total Shares Sold 2,229 296,929 313,427 517,850
Total Sell Value $52,561 $5,745,284 $6,055,258 $8,935,238
Total People Sold 1 9 9 11
Total Sell Transactions 2 65 67 96
End Date 2024-03-31 2023-12-29 2023-06-30 2022-06-30

   
Records found: 915
  Page 34 of 37  
Filer's Name Relation Title Off-Dir-10% Tran. Date Form Action Price Mkt Value D/I Shares Holdings
Rank

  
3m +/-  
Form
   Gale David C VP, Research & Development   •       –      –    2015-03-07 4 D $10.51 $10,962 D/D (1,043) 58,477     -
   Anderson Bruce G. VP, US Sales &Global Marketing   •       –      –    2015-03-07 4 D $10.51 $7,304 D/D (695) 42,106     -
   Anderson Steven G Executive Chairman   •       –      –    2015-03-07 4 D $10.51 $57,479 D/D (5,469) 1,316,250     -
   Capps Scott B VP, Clinical Research   •       –      –    2015-02-26 4 D $10.72 $8,930 D/D (833) 89,621     -
   Capps Scott B VP, Clinical Research   •       –      –    2015-02-26 4 A $0.00 $0 D/D 5,000 90,454     -
   Horton Amy Chief Accounting Officer   •       –      –    2015-02-26 4 D $10.72 $5,789 D/D (540) 71,567     -
   Horton Amy Chief Accounting Officer   •       –      –    2015-02-26 4 A $0.00 $0 D/D 3,334 72,107     -
   Lang David P. VP, Intl Sales & Marketing   •       –      –    2015-02-26 4 A $0.00 $0 D/D 5,000 73,441     -
   Fronk David VP, Regulatory Affairs   •       –      –    2015-02-26 4 D $10.72 $10,420 D/D (972) 111,776     -
   Fronk David VP, Regulatory Affairs   •       –      –    2015-02-26 4 A $0.00 $0 D/D 5,834 112,748     -
   Lee David Ashley Executive VP, COO & CFO   •       –      –    2015-02-26 4 D $10.72 $14,890 D/D (1,389) 241,458     -
   Lee David Ashley Executive VP, COO & CFO   •       –      –    2015-02-26 4 A $0.00 $0 D/D 8,334 242,847     -
   Anderson Bruce G. VP, US Sales &Global Marketing   •       –      –    2015-02-26 4 D $10.72 $8,930 D/D (833) 42,801     -
   Anderson Bruce G. VP, US Sales &Global Marketing   •       –      –    2015-02-26 4 A $0.00 $0 D/D 5,000 43,634     -
   Anderson Steven G Executive Chairman   •       –      –    2015-02-26 4 D $10.72 $46,075 D/D (4,298) 1,321,719     -
   Anderson Steven G Executive Chairman   •       –      –    2015-02-26 4 A $0.00 $0 D/D 20,834 1,326,017     -
   Gale David C VP, Research & Development   •       –      –    2015-02-26 4 D $10.72 $8,930 D/D (833) 59,520     -
   Gale David C VP, Research & Development   •       –      –    2015-02-26 4 A $0.00 $0 D/D 5,000 60,353     -
   Anderson Steven G Executive Chairman   •       –      –    2015-02-23 4 D $10.47 $620,274 D/D (59,243) 1,305,183     -
   Anderson Steven G Executive Chairman   •       –      –    2015-02-23 4 OE $9.73 $620,288 D/D 63,750 1,364,426     -
   Fronk David VP, Regulatory Affairs   •       –      –    2015-02-19 4 A $11.00 $94,963 D/D 8,633 104,829     -
   Lang David P. VP, Intl Sales & Marketing   •       –      –    2015-02-19 4 A $11.00 $81,389 D/D 7,399 68,441     -
   Mackin James P President & CEO   •       –      –    2015-02-19 4 A $11.00 $339,152 D/D 30,832 280,832     -
   Gale David C VP, Research & Development   •       –      –    2015-02-19 4 A $11.00 $81,389 D/D 7,399 55,353     -
   Capps Scott B VP, Clinical Research   •       –      –    2015-02-19 4 A $11.00 $81,389 D/D 7,399 85,454     -
  915 Records found
  Previous  30  31  32  33  34  35  36  37   
  Page 34 of 37
  Transaction Code Key: Ownership Code Key
  B - Buy AB - Automatic Buy D - Direct Ownership
  S - Sell AS - Automatic Sell I - Indirect Ownership
  OE - Options Exercised A - Acquired
  IO - Initital Ownership D - Disposed
 
 
    Copyright © 2024 j3sg.com | Disclaimer & Terms of use          Products & Service  About Us  Contact Us